HSA approves the first JAK inhibitor for moderate-to-severe atopic dermatitis: baricitinib (Olumiant)
Disease burden and current treatment landscape
Atopic dermatitis (AD) or atopic eczema is a common inflammatory skin condition that affects 20.8% of children aged 7 to 16 years in Singapore. While many children (about 70%) improve as . . .
Login or Sign Up as a healthcare professional to read the full article.
Also worth reading
Category: Health News
Created: 10/27/2020 12:00:00 AM
Last Editorial Review: 10/28/2020 12:00:00 AM